These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 31846429)

  • 1. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
    Sorbye H; Kong G; Grozinsky-Glasberg S
    Endocr Relat Cancer; 2020 Mar; 27(3):R67-R77. PubMed ID: 31846429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
    Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
    Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
    Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
    Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of
    Abou Jokh Casas E; Pubul Núñez V; Anido-Herranz U; Del Carmen Mallón Araujo M; Del Carmen Pombo Pasín M; Garrido Pumar M; Cabezas Agrícola JM; Cameselle-Teijeiro JM; Hilal A; Ruibal Morell Á
    World J Gastroenterol; 2020 Apr; 26(13):1513-1524. PubMed ID: 32308351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview and Current Status of Peptide Receptor Radionuclide Therapy.
    Bushnell DL; Bodeker KL
    Surg Oncol Clin N Am; 2020 Apr; 29(2):317-326. PubMed ID: 32151363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort.
    Lithgow K; Venkataraman H; Hughes S; Shah H; Kemp-Blake J; Vickrage S; Smith S; Humphries S; Elshafie M; Taniere P; Diaz-Cano S; Dasari BVM; Almond M; Ford S; Ayuk J; Shetty S; Shah T; Geh I
    Sci Rep; 2021 Sep; 11(1):17947. PubMed ID: 34504148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy.
    Yordanova A; Wicharz MM; Mayer K; Brossart P; Gonzalez-Carmona MA; Strassburg CP; Fimmers R; Essler M; Ahmadzadehfar H
    Clin Cancer Res; 2018 Oct; 24(19):4672-4679. PubMed ID: 29950352
    [No Abstract]   [Full Text] [Related]  

  • 12. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
    Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
    J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors.
    Ramage J; Naraev BG; Halfdanarson TR
    Semin Oncol; 2018 Aug; 45(4):236-248. PubMed ID: 30539715
    [No Abstract]   [Full Text] [Related]  

  • 14. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.
    Kwekkeboom DJ; Krenning EP
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):179-91. PubMed ID: 26614376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study.
    Trautwein NF; Hinterleitner C; Kiefer LS; Singer S; Mattern S; Schwenck J; Reischl G; Sipos B; Lauer UM; Dittmann H; Zender L; la Fougère C; Hinterleitner M
    Clin Nucl Med; 2024 Mar; 49(3):207-214. PubMed ID: 38271237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
    Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
    Fazio N; Milione M
    Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC).
    Sorbye H; Kong G; Grozinsky-Glasberg S; Strosberg J
    J Neuroendocrinol; 2024 Sep; ():e13443. PubMed ID: 39243213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy.
    Minczeles NS; Hofland J; de Herder WW; Brabander T
    Curr Oncol Rep; 2021 Mar; 23(4):46. PubMed ID: 33721105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.